FDA slims obesity pill chances
This article was originally published in Scrip
In issuing a complete response letter (CRL) to i today and requesting a further clinical study that assesses the cardiovascular risks to obese patients, the FDA not only went against the recommendations of its own Advisory Panel, but probably delivered the kiss of death to a tablet-based approach to treating obesity in the primary care setting for the foreseeable future. Having raised pre-clinical safety issues for Qnexa from Vivus in late January and having issued a CRL to Arena Pharmaceuticals' Lorcaserin last year asking for additional safety and efficacy information, Orexigen's drug was previously the last left standing in the approval queue that is now effectively empty.
You may also be interested in...
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.